康辰藥業(603590.SH):擬向國典醫藥增資2000萬元
格隆匯 11 月 27日丨康辰藥業(603590.SH)公佈,2020年11月26日,公司及深圳市紫新瑞創投管理中心(有限合夥)、山東省齊魯幹細胞工程有限公司,與國典醫藥及其原股東共同簽署了《增資協議》。此次增資完成後,國典醫藥註冊資本由原150萬元增至171萬元。公司擬出資人民幣2000萬元(其中,6萬元認繳新增註冊資本,其餘計入資本公積),將持有增資完成後國典醫藥3.5087%股權。
國典醫藥聚焦於世界先進的藥物篩選和藥效評價技術設備建設,建立基於人類幹細胞庫的藥物篩選和藥效評價平台,為神經性疾病、腫瘤、代謝性疾病等多種重大疾病的藥物研發及疾病患者個體提供藥物篩選和藥效評價平台(CRO服務)。此次投資完成後,雙方將在藥物研發等多方面開展合作。上述合作將有助於發揮雙方資源和專業優勢,提升公司藥物研發效率,增強競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.